MAPT and early-onset autosomal dominant Alzheimer disease: While PET represents the gold standard for monitoring late-stage Alzheimer’s disease when tau proteinopathy is present (the so-called T2 category of biomarkers; Braak stages III and VI), there is presently no suitable approach for monitoring pre-tangle tau (T1) in situ.